JP Morgan Chase
APUS

JP Morgan Chase’s Apimeds Pharmaceuticals US APUS Stock Holding History

JP Morgan Chase’s Portfolio APUS Stock Details APUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$14 – 7917
2025
Q3 		$14 Hold
1
– – ﹤0.01% 7304
2025
Q2 		$9 Buy
+1
New +$18 ﹤0.01% 6990

Other funds holding APUS

HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

JP Morgan Chase's APUS Position: Q4 2025 in Review

JP Morgan Chase sold out of Apimeds Pharmaceuticals US (APUS) in Q4 2025, closing a stake of 1 share — an estimated $14 sold.

JP Morgan Chase first reported a position in APUS in Q2 2025 and held it in 2 quarters. The position peaked at $14 in Q3 2025. 7 funds tracked by Wall St. Rank hold APUS as of Q4 2025.

  • JP Morgan Chase reported no remaining Apimeds Pharmaceuticals US position as of Q4 2025 after selling out during the quarter.
  • JP Morgan Chase sold 1 Apimeds Pharmaceuticals US share in Q4 2025, an estimated $14.
  • JP Morgan Chase first reported a position in Apimeds Pharmaceuticals US in Q2 2025 and held it in 2 quarters.
  • JP Morgan Chase's Apimeds Pharmaceuticals US position peaked at $14 in Q3 2025.
  • 7 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q4 2025.

Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.